Arcellx price target raised to $115 from $91 at Piper Sandler

Piper Sandler raised the firm’s price target on Arcellx (ACLX) to $115 from $91 and keeps an Overweight rating on the shares following Q3 results. The firm cited anito-cel’s latest data update as the reason behind the increase. The safety data for anito-cel appears to differentiate it from competitors as there have been no delayed neurotoxicities or non-immune effector cell-associated neurotoxicity syndrome events reported to date, Piper told investors in a research note.